Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Basal Cell Carcinoma · Skin Cancer · Cancer of the Skin, Basal Cell · Cancer of the Skin · Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 92 (final count)
- Started
- Feb 1, 2022
- Main results expected
- Apr 15, 2024
- Fully finished
- Apr 15, 2024
- Results posted
- Jun 18, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events
Measured over: Up to 9 weeks
Part 1: Percentage of Subjects With Dose-limiting Toxicities (DLTs)
Measured over: Day 4 (Safety Assessment)
Part 1: Percentage of Subjects With Cutaneous Reaction by Maximum Severity
Measured over: Up to 9 weeks
Part 2: Percent of Subjects With Adverse Events
Measured over: Up to 15 weeks
Part 2: Percentage of Subjects With Study Discontinuations Due to Adverse Events
Measured over: Up to 15 weeks
Part 2: Percent of Subjects With Treatment Related Adverse Events of Special Interest (TRAEs SI)
Measured over: Treatment Days up to 2 weeks
Part 2: Percentage of Subjects With Cutaneous Reaction by Maximum Severity
Measured over: Up to 105 days
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05188729 · record last updated 2025-06-18 · checked 2026-11-09 15:47 UTC